Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD

Samuel Dagogo-Jack, R. S.C. Rodger, P. Kendall-Taylor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Epidermal growth factor (EGF) was measured in the saliva of 36 patients with chronic renal failure (CRF) and 29 matched control subjects. Salivary EGF in controls was 0.65 ± 0.009 nmol/L compared with 0.99±0.24 nmol/L in nondialyzed CRF patients, 1.15 ± 0.23 in hemodialyzed patients and 1.96 ± 0.25 (p < 0.01, Wilcoxon Rank Sum Test) in CAPD-treated patients. On Sephadex chromatography, the major peak of immunoreactive EGF from patient and control saliva samples coeluted with purified human EGF. We conclude that salivary concentrations of human EGF are significantly elevated in end-stage renal failure, particularly in patients treated by CAPD.

Original languageEnglish (US)
Pages (from-to)270-273
Number of pages4
JournalPeritoneal Dialysis International
Volume11
Issue number3
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Continuous Ambulatory Peritoneal Dialysis
Epidermal Growth Factor
Chronic Kidney Failure
Nonparametric Statistics
Saliva
Chromatography

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD. / Dagogo-Jack, Samuel; Rodger, R. S.C.; Kendall-Taylor, P.

In: Peritoneal Dialysis International, Vol. 11, No. 3, 01.01.1991, p. 270-273.

Research output: Contribution to journalArticle

@article{ec1f581aa4c6476f99fffcbbabd26235,
title = "Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD",
abstract = "Epidermal growth factor (EGF) was measured in the saliva of 36 patients with chronic renal failure (CRF) and 29 matched control subjects. Salivary EGF in controls was 0.65 ± 0.009 nmol/L compared with 0.99±0.24 nmol/L in nondialyzed CRF patients, 1.15 ± 0.23 in hemodialyzed patients and 1.96 ± 0.25 (p < 0.01, Wilcoxon Rank Sum Test) in CAPD-treated patients. On Sephadex chromatography, the major peak of immunoreactive EGF from patient and control saliva samples coeluted with purified human EGF. We conclude that salivary concentrations of human EGF are significantly elevated in end-stage renal failure, particularly in patients treated by CAPD.",
author = "Samuel Dagogo-Jack and Rodger, {R. S.C.} and P. Kendall-Taylor",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "270--273",
journal = "Peritoneal Dialysis International",
issn = "0896-8608",
publisher = "Multimed Inc.",
number = "3",

}

TY - JOUR

T1 - Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD

AU - Dagogo-Jack, Samuel

AU - Rodger, R. S.C.

AU - Kendall-Taylor, P.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Epidermal growth factor (EGF) was measured in the saliva of 36 patients with chronic renal failure (CRF) and 29 matched control subjects. Salivary EGF in controls was 0.65 ± 0.009 nmol/L compared with 0.99±0.24 nmol/L in nondialyzed CRF patients, 1.15 ± 0.23 in hemodialyzed patients and 1.96 ± 0.25 (p < 0.01, Wilcoxon Rank Sum Test) in CAPD-treated patients. On Sephadex chromatography, the major peak of immunoreactive EGF from patient and control saliva samples coeluted with purified human EGF. We conclude that salivary concentrations of human EGF are significantly elevated in end-stage renal failure, particularly in patients treated by CAPD.

AB - Epidermal growth factor (EGF) was measured in the saliva of 36 patients with chronic renal failure (CRF) and 29 matched control subjects. Salivary EGF in controls was 0.65 ± 0.009 nmol/L compared with 0.99±0.24 nmol/L in nondialyzed CRF patients, 1.15 ± 0.23 in hemodialyzed patients and 1.96 ± 0.25 (p < 0.01, Wilcoxon Rank Sum Test) in CAPD-treated patients. On Sephadex chromatography, the major peak of immunoreactive EGF from patient and control saliva samples coeluted with purified human EGF. We conclude that salivary concentrations of human EGF are significantly elevated in end-stage renal failure, particularly in patients treated by CAPD.

UR - http://www.scopus.com/inward/record.url?scp=0025784955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025784955&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 270

EP - 273

JO - Peritoneal Dialysis International

JF - Peritoneal Dialysis International

SN - 0896-8608

IS - 3

ER -